Abstract: Provided is a method for producing a compound expressed by the following formula (3): [where R1 represents a hydrogen atom or C1-4 alkyl group, and R2 represents C1-4 alkyl group, C1-4 alkoxy group, aryl group, aryloxy group or benzyloxy group], the method comprising a reaction of dehydro-condensing a compound expressed by the following formula (1) and a compound expressed by the following formula (2): while being converted to a desired geometric isomer in the presence or absence of an acid catalyst, under a condition that an organic solvent to be used for the reaction is a mixed solvent of acetic acid and a solvent selected from the group consisting of toluene, xylene and chlorobenzene.
Abstract: To provide a novel imino derivative capable of being an insecticide compound which is excellent in characteristics such as sustained effects and a broad spectrum. An imino derivative represented by Formula (A) shown below: wherein “Ar” represents a heterocyclic group which may have a substituent on the ring, “X” represents a sulfur atom or CH2, NR; “R” represents a hydrogen atom or an alkyl group; “Ya” is selected from “C(?S)NR1R2”, “C(?S)SR3”, “C(?O)SR4”, “C(?S)OR4”, “SO2Z?”, and “OZ?”; and, each of “R1” to “R4”, “Z?”, and “Z?” represents a hydrogen atom or a certain substituent; is provided.
Type:
Application
Filed:
January 6, 2011
Publication date:
November 1, 2012
Applicants:
MEIJI SEIKA PHARMA CO., LTD., GIFU UNIVERSITY
Abstract: A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci).
Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
Abstract: Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].
Abstract: A prophylactic or therapeutic agent for a viral disease, characterized by combining 22?-methoxyolean-12-ene-3?,24(4?)-diol with an interferon as active ingredients is disclosed. The prophylactic or therapeutic agent of the present invention exhibits a high therapeutic effect by administering 22?-methoxyolean-12-ene-3?,24(4?)-diol and interferon as a combination thereof.
Abstract: Disclosed is a process for producing compound C represented by formula C: wherein R? represents straight chain, branched chain, or cyclic C2-6 alkylcarbonyl, wherein R1b is used as a protective group for hydroxyl at the 7-position of compound C.
Abstract: A novel endoglucanase PPCE derived from Penicillium pinophilum, a cellulase preparation containing the endoglucanase PPCE, and a method of treating a cellulose-containing fabric utilizing the endoglucanase PPCE or the cellulase preparation, are disclosed. The endoglucanase PPCE is highly active to a fabric, and has a low optimum temperature and a strongly acidic optimum pH.
Abstract: Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide.
Type:
Grant
Filed:
September 3, 2008
Date of Patent:
July 24, 2012
Assignee:
Meiji Seika Pharma Co., Ltd
Inventors:
Teruhisa Yoshizawa, Akiko Miyoshi, Masato Ota
Abstract: Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for ?-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R1 represents CO2R, CO2M, or CONH2, wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R2 represents a benzyl group or an allyl group.
Abstract: Disclosed is a compound usable as a pest control agent and has excellent pest control activity. A compound represented by formula (I) has excellent pest control activity. The compound or an agriculturally or horticulturally acceptable salt thereof is thus useful as a pest control agent.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
June 19, 2012
Assignees:
Meiji Seika Pharma Co., Ltd., The Kitasato Institute
Abstract: By combination of hydrophobic chromatography and strongly basic anion-exchange chromatography, a novel, highly hydrophobic ?-glucosidase was successfully identified from Acremonium cellulolyticus. Further, a gene corresponding to the identified ?-glucosidase was isolated. When multiple modifications were introduced into the base sequence of the gene, the gene was successfully expressed in Trichoderma viride at a high level, and the expression product successfully exhibited a high ?-glucosidase activity.
Abstract: It is found that even refractory chronic hepatitis C can be treated effectively and safely by administering an effective amount of a combination of 22?-methoxyolean-12-ene-3?,24(4?)-diol with an IFN.
Abstract: By having a cellulase preparation comprising at least a certain amount of endoglucanases derived from two different types of microorganisms, the cellulase preparation can be provided with a higher activity and a wider pH property than those of cellulase preparations each containing one of the endoglucanases alone. Moreover, by introducing and expressing simultaneously two different types of cellulase genes in a single host cell, a cellulase preparation having a high activity and a wide pH property can be produced easily.
Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.
Type:
Grant
Filed:
June 1, 2007
Date of Patent:
April 3, 2012
Assignees:
Meiji Seika Pharma Co., Ltd., Microbial Chemistry Research Foundation
Abstract: The present invention is a process for producing optically active aminophosphinylbutanoic acids represented by the formula (2), comprising asymmetrically hydrogenating a compound represented by the formula (1) in the presence of a ruthenium-optically active phosphine complex, a process for the production thereof, and a compound useful in a herbicide such as L-AHPB that can be produced with good efficiency and high asymmetric yield.
Type:
Grant
Filed:
September 3, 2007
Date of Patent:
December 13, 2011
Assignees:
Meiji Seika Pharma Co., Ltd., Takasago International Corporation
Abstract: A fusion collagenase in which an affinity tag is added to the carboxyl terminal of a collagenase was expressed as a recombinant protein. It was found that a collagenase having a collagen-binding domain can be selectively collected by purifying the obtained fusion collagenase by affinity chromatography.
Abstract: Disclosed is a composition for use in controlling ectoparasites, comprising as an active ingredient at least one of compounds represented by formula (I) or (III) or salts thereof. The present invention provides a composition for use in controlling ectoparasites that has excellent ectoparasite control effect and is highly safe.